BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: DeMatteo RP. Nanoneoadjuvant therapy of gastrointestinal stromal tumor (GIST). Ann Surg Oncol. 2009;16:799-800. [PMID: 19169754 DOI: 10.1245/s10434-009-0316-9] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 0.7] [Reference Citation Analysis]
Number Citing Articles
1 von Mehren M, Widmer N. Correlations between imatinib pharmacokinetics, pharmacodynamics, adherence, and clinical response in advanced metastatic gastrointestinal stromal tumor (GIST): an emerging role for drug blood level testing? Cancer Treat Rev 2011;37:291-9. [PMID: 21078547 DOI: 10.1016/j.ctrv.2010.10.001] [Cited by in Crossref: 43] [Cited by in F6Publishing: 38] [Article Influence: 3.6] [Reference Citation Analysis]
2 Kong Y, Ma XW, Zhang QQ, Zhao Y, Feng HL. Gastrointestinal stromal tumor with multisegmental spinal metastases as first presentation: A case report and review of the literature. World J Clin Cases 2021; 9(6): 1490-1498 [PMID: 33644220 DOI: 10.12998/wjcc.v9.i6.1490] [Reference Citation Analysis]
3 Shaib YH, Rugge M, Graham DY, Genta RM. Management of gastric polyps: an endoscopy-based approach. Clin Gastroenterol Hepatol 2013;11:1374-84. [PMID: 23583466 DOI: 10.1016/j.cgh.2013.03.019] [Cited by in Crossref: 58] [Cited by in F6Publishing: 49] [Article Influence: 6.4] [Reference Citation Analysis]
4 Blanchard Z, Mullins N, Ellipeddi P, Lage JM, McKinney S, El-Etriby R, Zhang X, Isokpehi R, Hernandez B, Elshamy WM. Geminin overexpression promotes imatinib sensitive breast cancer: a novel treatment approach for aggressive breast cancers, including a subset of triple negative. PLoS One 2014;9:e95663. [PMID: 24789045 DOI: 10.1371/journal.pone.0095663] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 2.4] [Reference Citation Analysis]
5 Porter MG, Stoeger SM. Atypical Colorectal Neoplasms. Surgical Clinics of North America 2017;97:641-56. [DOI: 10.1016/j.suc.2017.01.011] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
6 Shah MA, Kurtz RC. Upper gastrointestinal cancer predisposition syndromes. Hematol Oncol Clin North Am 2010;24:815-35. [PMID: 20816576 DOI: 10.1016/j.hoc.2010.06.007] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
7 Lamba G, Gupta R, Lee B, Ambrale S, Liu D. Current management and prognostic features for gastrointestinal stromal tumor (GIST). Exp Hematol Oncol. 2012;1:14. [PMID: 23210689 DOI: 10.1186/2162-3619-1-14] [Cited by in Crossref: 37] [Cited by in F6Publishing: 36] [Article Influence: 3.7] [Reference Citation Analysis]
8 Ganguly SS, Fiore LS, Sims JT, Friend JW, Srinivasan D, Thacker MA, Cibull ML, Wang C, Novak M, Kaetzel DM, Plattner R. c-Abl and Arg are activated in human primary melanomas, promote melanoma cell invasion via distinct pathways, and drive metastatic progression. Oncogene 2012;31:1804-16. [PMID: 21892207 DOI: 10.1038/onc.2011.361] [Cited by in Crossref: 43] [Cited by in F6Publishing: 50] [Article Influence: 3.9] [Reference Citation Analysis]
9 Parab TM, DeRogatis MJ, Boaz AM, Grasso SA, Issack PS, Duarte DA, Urayeneza O, Vahdat S, Qiao JH, Hinika GS. Gastrointestinal stromal tumors: a comprehensive review. J Gastrointest Oncol. 2019;10:144-154. [PMID: 30788170 DOI: 10.21037/jgo.2018.08.20] [Cited by in Crossref: 43] [Cited by in F6Publishing: 38] [Article Influence: 10.8] [Reference Citation Analysis]